How Singapore's public hospitals buy diagnostics: central bundling, discount demands and when a lab switches platform
Summary
- The buyer is no longer the doctor alone: the Ministry of Health set up a procurement agency to bundle purchasing across the public institutions, and its bulk buying and rate negotiation are now stated policy. 1 2
- Procurement opens with deep discount demands, may reopen bidding after the first round, and negotiates from an assumed supplier margin. 3 4
- Clusters have been funded by capitation since 2023, and the health budget of $21 billion is estimated to pass $30 billion by 2030, so cost pressure on diagnostics is structural. 1 5
- Reagents follow the analyser platform, so the real fight is the platform decision; suppliers who bundle staff and training and talk to procurement as well as doctors gained share. 6 7
- Registration times set the entry timetable: Class D full route is 310 working days, and the Malaysia-Singapore pilot offered up to 30% shorter review for devices already registered next door. 8 9
- Medical supplies are about 12% of total healthcare costs, and diversifying the supplier base across regions is official policy, which keeps the door open for new origins. 2
Transcript
01What changed on the buying side
You led purchasing for diagnostics at a public cluster. What would you tell an outsider first about how these hospitals buy?
That the doctor is no longer the customer. When procurement was consolidated across the cluster, the power moved from the clinicians to our office. We used to process paperwork for the doctors. After that we asked why, and made them justify the request, and we were willing to switch a brand rather than defer to what the department was used to. 10
Today the structure is one level higher again. The Ministry of Health set up the Agency of Logistics and Procurement Services to bundle procurement across the public institutions where practical, and it says that its contracting with multiple suppliers also helps supply resilience. 1 So you are no longer selling to a lab head in one hospital. You are selling into a system that wants to buy once and buy well. 2
How do these buyers open a negotiation?
Hard. The opening position is a demand for a deep discount, and if the first round does not give it, the bidding may be reopened. 3 I have seen suppliers surprised by this because their regional price list assumed the old way of doing business. If you arrive without a second price already approved by your head office, you will lose a week and some credibility. 3
The ministry's own wording is plain: the agency leverages bulk purchasing across the public healthcare system and works closely with suppliers to negotiate better rates and stabilise prices. 2 Read that as 'volume for price'. Nobody is embarrassed about it. 3
02Why the money is tight
Why is there so much pressure on price in a rich country?
Because the bill is rising and everybody knows it. The Minister for Health said in March 2025 that that year's healthcare budget was $21 billion, second only to defence, and that by 2030 it is estimated at over $30 billion, at least another $10 billion. He added that the expenditure curve must not escalate uncontrollably. 5 When the person at the top says that, a procurement office hears a target. 10
There is a second driver. Since 2023 the public clusters have been funded by capitation, and the ministry says this encourages them to get more value through productivity gains. 1 A cluster that is paid per head, not per procedure, treats every reagent line as a cost to manage and not as revenue to protect. 11
Does the ministry's own spending show this squeeze?
I would be careful reading too much into one number. The ministry's FY2025 operating expenditure was first estimated at $18.80 billion and later revised to $18.49 billion, which is $310 million lower. 12 That is a whole-ministry figure, not a diagnostics figure, and I cannot tell you how much of it came from purchasing. 12
What I can say is the share of the bill we are fighting over. The ministry says medical supplies make up about 12% of total healthcare costs. 2 That is big enough to be worth a dedicated agency, and small enough that nobody expects to fix the whole budget with it. So the pressure is steady, not dramatic. 2
03Margins, discounts and where the room is
How does a purchasing office think about the supplier's margin?
We looked at the supplier's financial results and we worked from an assumed margin. We did not have the real number for any one product line, and I would not claim that we did. 4 But having a number in the room changes the conversation. A supplier who says 'we cannot go lower' gets asked to show why, and the assumed margin sets how far we think the real floor is. 4
A mistake outsiders make is to answer the discount demand with a small, slow concession. We are patient, we can reopen the bidding, and a trickle of 'final offers' teaches us the first offer was padded. 3 Better to decide at the start what you will trade for volume, term or bundled service, and to put that on the table once. 7
Do suppliers ever accept thin margins on purpose?
Yes, and I understood why. Singapore is a showcase. Suppliers bring customers from other countries to see a Singapore hospital laboratory running their platform, so they defend an account even when the margin is thin. 13 I cannot tell you which suppliers do this, it depends on the account and on the regional head's budget. 13
It also explains why the market moves in jumps. When a few large accounts change hands, supplier shares swing markedly, so each tender feels like a battle for the whole year. 14 As a buyer, I used that feeling. I never said so, but I knew who needed the win. 14
04Platforms, reagents and the cost of switching
Why aren't reagents just tendered like any other consumable?
Because the reagent follows the machine. Laboratories run different equipment, so reagents are hard to tender across sites, and the analyser platform decides whose reagents we buy. 6 If a cluster wants one reagent price for everything, it first has to decide on the platform. That is a much bigger decision than a price round. 6
So the real negotiation is at placement. Whoever places the analyser wins the reagent stream for the contract term, and the instrument price is often the smaller part. I would tell a newcomer to price the placement and the reagent together and to expect procurement to look at both. 6 7
What would make you switch a lab's platform to another supplier?
Not the brochure. Lab users rate the major suppliers similarly on reliability, repair quality and service, and perhaps one stands out slightly. 15 When the service is about equal, price and bundle decide, and that is where a procurement office is comfortable. I was prepared to move a platform when the lab's performance would not suffer and the saving was clear. 10
The lab heads still have a say, and they care about turnaround and automation. Suppliers that sell workflow solutions and consulting alongside the instrument speak their language, and that carries weight in the room. 16 A good bid answers both people: the lab head on turnaround, and me on cost. 16
05Volumes, bundles and who wins
Does test volume also move the reagent business?
Yes, and many suppliers forget it. When the cluster keeps better records, it can audit and cut unnecessary tests, and that lowers volumes. 17 Hospitals are also pushed by their financing, since co-payment and savings accounts, with subsidies tied to diagnosis groups, make them watch the number of tests. 11 So I would not sign a volume forecast built on last year's test count. 17
I remember suppliers who had a take-or-pay structure built around growth. When the volumes fell, nobody was happy. A cost-per-reportable-result deal shares the risk and is easier to defend in a review. 17
Who actually wins these tenders?
The supplier who talks to procurement as well as the doctors. One supplier gained share by courting the purchasing office with low prices and bundled solutions such as staff and training, while others still worked only on the doctors. 7 Doctors still matter, but they no longer decide alone. 10
Distributors have a harder time. Major manufacturers sell direct here, and a distributor usually holds a single-country franchise and cannot spread its costs. 18 If you are a distributor, you need to bring something the maker's direct team cannot, such as a niche line or a service. 18
06Rules, registration and the supplier base
How do tenders reach suppliers, and what do I need before I can bid?
On the process side I can only point to the general rule for government procurement. The Ministry of Finance says the government publishes all requirements, procedures and evaluation criteria on GeBIZ so suppliers know what is needed and how bids are assessed. 19 I cannot tell you from memory which cluster tender follows which route. Check each one. 19
On the device side, the product must be registered. The route depends on risk class, on prior approvals from overseas reference regulators and on the safe marketing history. With no prior approval it is the full route, with approval from at least one reference agency it can be the abridged route. 20 Class A devices are exempt but need a product notification. 20
How long does that take?
Check the table, because it is easy to underestimate. In working days the full route for Class C is 220 and for Class D 310, the Class D expedited route is 180, and a Class B device can be immediate. 8 A reagent that belongs in a higher class can lose most of a tender year before the first sale. 8
There is some help for suppliers already registered in Malaysia. A pilot ran from 1 September 2025 to 28 February 2026 for Class B, C and D devices, with an abridged pathway offering up to 30% shorter review times for devices registered with Malaysia's authority. 9 I do not know yet how the ministries will continue it, so I would ask the regulator. 9
Does the government want new supplier origins?
It says so. The ministry has diversified its supplier base, sourcing from multiple regions including Asia-Pacific, Europe and the Americas. 2 For a Japanese, Korean or Chinese maker, that is a real opening, but being on the list is not the same as winning. You still have to beat the incumbent on the bundle. 7
07Advice to a newcomer, and what worries me
A new supplier wants to enter the public hospital channel. What should it do?
First, make the offer for procurement, not only for the lab. Bring a price you have already cleared, a service package with staff and training, and a clear answer on what you will do if volumes fall. 7 Second, expect to be asked to justify your price, and prepare the answer. 4
Third, do not assume a good relationship with a clinician will carry you. Procurement challenges requests and is willing to move a brand. 10 And do not expect a big first order. Start with one platform, perform, and let the account grow. 14
What would change your mind about how hard this market is, and what worries you?
If the agency began to run one national reagent contract, I would change my view of the market altogether. Today reagents follow the platform and the labs run different equipment, so it is not simple. 6 Bundling is the stated direction, though, and the ministry has said so. 1
What worries me is the squeeze on the supplier's service. When prices are pushed down for years, the first thing to thin out is the visit that nobody can see in a tender. The ministry rightly stresses supply resilience and multiple suppliers. 1 I hope buyers keep in mind that cheap and dependable are not the same thing. 15
Sources and basis
- 1Ministry of Health written parliamentary answer, 14 October 2025: MOH set up the Agency of Logistics and Procurement Services to bundle procurement across Public Health Institutions where practical; its procurement also improves supply resilience by contracting with multiple suppliers; since 2023 public healthcare clusters have been funded through capitation, which MOH says encourages clusters to get more value through productivity gainsPublic source · Ministry of Health, parliamentary reply on multiple sourcing for drugs, consumables and laboratory services, 14 Oct 2025 · link
- 2Ministry of Health written answer, 6 May 2026: the Agency of Logistics and Procurement Services leverages bulk purchasing across the public healthcare system and works closely with suppliers to negotiate better rates and stabilise prices; MOH has diversified its supplier base, sourcing from multiple regions including Asia-Pacific, Europe and the Americas; medical supplies from the Straits of Hormuz route are well below 1% of total medical supplies; medical supplies make up about 12% of total healthcare costsPublic source · Ministry of Health, parliamentary reply on medical supply chain and procurement cost pressures, 6 May 2026 · link
- 3Consolidated purchasing opens negotiations with demands for deep discounts and sometimes reopens the bidding after the first roundKIRA field interviews · KIRA field interviews, Singapore hospital clusters
- 4Purchasing offices research suppliers' financial results and negotiate from an assumed supplier marginKIRA field interviews · KIRA field interviews, Singapore hospital clusters
- 5Minister for Health, Committee of Supply debate, 7 March 2025: this year's healthcare budget is $21 billion, second behind the Ministry of Defence; by 2030 it is estimated to be over $30 billion, at least another $10 billion increase; the healthcare expenditure curve must not be allowed to escalate uncontrollablyPublic source · Ministry of Health, Committee of Supply speech, 7 Mar 2025 · link
- 6Reagents are hard to tender across sites because laboratories run different equipment, so the analyser platform decides which supplier's reagents are boughtKIRA field interviews · KIRA field interviews, Singapore hospital clusters
- 7A supplier that courted the purchasing office with low prices and bundled solutions such as staff and training gained share, while suppliers that only courted the doctors lost groundKIRA field interviews · KIRA field interviews, Singapore hospital clusters
- 8Health Sciences Authority fee and turnaround-time table, last updated 26 March 2026, in working days: Class B immediate route immediate upon submission, abridged 100, full 160; Class C expedited 120, abridged 160, full 220; Class D expedited 180, abridged 220, full 310Public source · Health Sciences Authority, fees and turnaround time for medical devices, page updated 26 Mar 2026 · link
- 9Health Sciences Authority announcement, 22 August 2025: Malaysia and Singapore signed a memorandum of understanding and launched a six-month regulatory reliance pilot from 1 September 2025 to 28 February 2026 for Class B, C and D medical devices; in Singapore, devices registered with Malaysia's Medical Device Authority get an abridged review pathway with up to 30% shorter review times; in Malaysia, devices registered with HSA can use a verification route with review expected in 30 working days instead of 60Public source · Health Sciences Authority, announcement on the Malaysia-Singapore reliance pilot, 22 Aug 2025 · link
- 10Once purchasing is consolidated across a hospital cluster, power moves from the clinicians to the procurement office, which asks doctors to justify their requests and is willing to switch brands instead of deferring to familiarityKIRA field interviews · KIRA field interviews, Singapore hospital clusters
- 11Co-payment and savings-account financing, with subsidies tied to diagnosis groups, push hospitals to control the number of testsKIRA field interviews · KIRA field interviews, Singapore hospital clusters
- 12Ministry of Health written answer, 4 March 2026: FY2025 operating expenditure of the Ministry of Health was initially estimated at $18.80 billion and revised to $18.49 billion, $310 million lower than the initial estimatePublic source · Ministry of Health, parliamentary reply on operating expenditure, 4 Mar 2026 · link
- 13Suppliers defend accounts in Singapore even at thin margins, because the market serves as a regional showcase for visiting customers from other countriesKIRA field interviews · KIRA field interviews, Singapore diagnostics suppliers
- 14In a concentrated hospital market, a few large account wins or losses swing supplier market shares markedlyKIRA field interviews · KIRA field interviews, Singapore diagnostics suppliers
- 15Laboratory users rate the major suppliers similarly on reliability, repair quality and service, with at most one standing out slightlyKIRA field interviews · KIRA field interviews, Singapore laboratory heads
- 16Suppliers increasingly sell workflow solutions and consulting alongside instruments, and central laboratory automation with fast turnaround matters to laboratory headsKIRA field interviews · KIRA field interviews, Singapore laboratory heads
- 17Better records let a cluster audit and cut unnecessary tests, which lowers test volumes and so reagent volumesKIRA field interviews · KIRA field interviews, Singapore hospital clusters
- 18Major manufacturers sell direct in Singapore; distributors usually hold single-country franchises and cannot spread their costs across a regionKIRA field interviews · KIRA field interviews, Singapore diagnostics suppliers
- 19Ministry of Finance government procurement overview, last updated 22 October 2025: the government publishes all requirements, procedures and evaluation criteria on GeBIZ so that suppliers know what is needed and how bids are assessed (a statement about government procurement in general)Public source · Ministry of Finance, government procurement overview, page updated 22 Oct 2025 · link
- 20Health Sciences Authority registration overview, last updated 13 March 2026: each device is registered through a specific evaluation route set by its risk classification, the prior approvals from overseas reference regulators and its safe marketing history; the full route applies where there is no prior approval, the abridged route where there is approval from at least one reference agency; Class A devices are exempt from registration but need a product notification; IVD assays for HIV screening and diagnosis and for blood or tissue donor compatibility testing cannot use the expedited Class D route, while IVD analysers are not in that exclusionPublic source · Health Sciences Authority, registration overview of medical devices, page updated 13 Mar 2026 · link